share_log

Panbela Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Panbela Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Panbela Therapeutics | DEFR14A：修正後委託徵集材料
美股sec公告 ·  05/06 16:17
Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc. has filed a definitive proxy statement with the SEC to amend its original proxy statement regarding its Special Meeting of Stockholders, now rescheduled from May 3, 2024, to May 28, 2024. The amendment reflects the rescheduling, a change in the record date for determining stockholders entitled to vote from March 27, 2024, to April 24, 2024, and the issuance of one share of Series A Preferred Stock with specific voting rights. The Special Meeting's agenda includes a proposal for a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-45, as determined by the Board, and the potential adjournment of the meeting if necessary to solicit additional proxies. The reverse stock split aims to increase the per-share market price to meet national securities exchange listing requirements following Nasdaq's notification of delisting. Stockholders are urged to vote using the new proxy card provided, as previous ones will be disregarded. The meeting will be held virtually, and stockholders must register by May 25, 2024, to attend.
Panbela Therapeutics, Inc. has filed a definitive proxy statement with the SEC to amend its original proxy statement regarding its Special Meeting of Stockholders, now rescheduled from May 3, 2024, to May 28, 2024. The amendment reflects the rescheduling, a change in the record date for determining stockholders entitled to vote from March 27, 2024, to April 24, 2024, and the issuance of one share of Series A Preferred Stock with specific voting rights. The Special Meeting's agenda includes a proposal for a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-45, as determined by the Board, and the potential adjournment of the meeting if necessary to solicit additional proxies. The reverse stock split aims to increase the per-share market price to meet national securities exchange listing requirements following Nasdaq's notification of delisting. Stockholders are urged to vote using the new proxy card provided, as previous ones will be disregarded. The meeting will be held virtually, and stockholders must register by May 25, 2024, to attend.
Panbela Therapeutics, Inc.已向美國證券交易委員會提交了最終委託書，以修改其關於其股東特別會議的原始委託聲明，該特別會議現已從2024年5月3日改期至2024年5月28日。該修正案反映了重新安排、確定有權投票的股東的記錄日期從2024年3月27日更改至2024年4月24日，以及發行一股具有特定投票權的A系列優先股。特別會議的議程包括一項提案，由董事會決定，以1比10和1比45的比例對普通股進行反向拆分，以及在必要時可能休會以徵集更多代理人。反向股票拆分旨在提高每股市場價格，以滿足納斯達克退市通知後的國家證券交易所上市要求。敦促股東使用提供的新代理卡進行投票，因爲以前的代理卡將被忽略。會議將以虛擬方式舉行，股東必須在2024年5月25日之前註冊才能參加。
Panbela Therapeutics, Inc.已向美國證券交易委員會提交了最終委託書，以修改其關於其股東特別會議的原始委託聲明，該特別會議現已從2024年5月3日改期至2024年5月28日。該修正案反映了重新安排、確定有權投票的股東的記錄日期從2024年3月27日更改至2024年4月24日，以及發行一股具有特定投票權的A系列優先股。特別會議的議程包括一項提案，由董事會決定，以1比10和1比45的比例對普通股進行反向拆分，以及在必要時可能休會以徵集更多代理人。反向股票拆分旨在提高每股市場價格，以滿足納斯達克退市通知後的國家證券交易所上市要求。敦促股東使用提供的新代理卡進行投票，因爲以前的代理卡將被忽略。會議將以虛擬方式舉行，股東必須在2024年5月25日之前註冊才能參加。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息